Puma Biotechnology stock gets higher 2026 Nerlynx outlook

Puma Biotechnology raised its 2026 sales outlook for Nerlynx after product sales increased in the first half of the year, according to a Zacks analysis published on October 20, 2026. The update gives investors a clearer view of the commercial outlook ahead of Puma's third-quarter reporting.

In the first six months of 2026, Nerlynx sales rose 3.5 percent year over year to USD 95.5 million. Management's updated full-year expectation calls for Nerlynx sales of USD 205 million to USD 209 million, compared with the previous range of USD 202 million to USD 206 million.

Nerlynx remains the earnings anchor

Nerlynx is Puma's marketed breast-cancer treatment and remains the company's principal commercial driver. Zacks said Puma expects third-quarter Nerlynx net product revenue of USD 54 million to USD 56 million, making prescription demand and revenue execution central issues for the next results update.

The outlook also leaves room for execution risk. The product competes in the targeted breast-cancer market, while Puma's revenue profile remains concentrated around Nerlynx and related royalty income. Investors therefore have to weigh the improved sales trajectory against the company's dependence on one marketed product.

Alisertib adds development optionality

Puma is developing alisertib, an Aurora kinase A inhibitor, in mid-stage studies for breast cancer and small-cell lung cancer. Zacks reported that the company is evaluating the candidate in combination with endocrine treatment in the ALISCA-Breast1 study and in separate small-cell lung-cancer programs. These programs could broaden Puma's longer-term growth prospects, but they remain development-stage assets and do not yet contribute commercial revenue.

For investors, the key distinction is between current product execution and pipeline potential. Nerlynx sales provide the near-term operating base, while alisertib progress could influence the longer-term valuation if clinical development produces supportive evidence.

Puma Biotechnology's real-time quote of Puma Biotechnology stock is available separately.

The broader market backdrop can be followed through the S&P 500.

Further company-specific coverage is available in more news and analyses on Puma Biotechnology stock.